哈尔滨医科大学附属第一医院
First Affiliated Hospital of Harbin Medical University
在本站收录的 61 种疾病中,这家医院列在其中 23 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
哈尔滨医科大学附属第一医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 肝细胞癌Hepatocellular carcinoma31 篇牵头论文
- 肺癌Lung cancer25 篇牵头论文
- 胰腺癌Pancreatic cancer23 篇牵头论文
- 乳腺癌Breast cancer23 篇牵头论文
- 胶质瘤Glioma35 篇牵头论文
- 肝母细胞瘤Hepatoblastoma0 篇牵头论文
- 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
- 骨肉瘤Osteosarcoma21 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
- 神经母细胞瘤Neuroblastoma3 篇牵头论文
- 尤文肉瘤Ewing sarcoma1 篇牵头论文
- 多发性骨髓瘤Multiple myeloma4 篇牵头论文
- B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia2 篇牵头论文
- 淋巴瘤Lymphoma1 篇牵头论文牵头 1 项开放试验
- 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
- 烟雾病Moyamoya disease2 篇牵头论文
- 冠心病Coronary heart disease8 篇牵头论文
- 脊柱侧弯Scoliosis2 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis2 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis11 篇牵头论文
- 白塞病Behçet disease1 篇牵头论文
- IgA 肾病IgA nephropathy2 篇牵头论文
- 先天性巨结肠Hirschsprung disease1 篇牵头论文
未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、胃癌、脊索瘤、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、肝豆状核变性、胆道闭锁、先天性心脏病、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 31 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 4 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文31
- A STT3A-dependent PD-L1 glycosylation modification mediated by GMPS drives tumor immune evasion in hepatocellular carcinoma.
- Periodontitis and Hepatocellular Carcinoma: A Two-Sample Mendelian Randomisation Study.
- Melanin@PLGA/Nuciferine Nanoparticles for Enhanced Photothermal Therapy of Hepatocellular Carcinoma by Promoting Autophagy.
- Hepatocellular Carcinoma LINC01116 Outcompetes T Cells for Linoleic Acid and Accelerates Tumor Progression.
- DEAD-Box Helicase 17 circRNA (circDDX17) Reduces Sorafenib Resistance and Tumorigenesis in Hepatocellular Carcinoma.
- RGS19 activates the MYH9/β-catenin/c-Myc positive feedback loop in hepatocellular carcinoma.
- FBW7-Mediated Degradation of CHD3 Suppresses Hepatocellular Carcinoma Metastasis and Stemness to Enhance Oxaliplatin Sensitivity.
- Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC.
- RRP8, associated with immune infiltration, is a prospective therapeutic target in hepatocellular carcinoma.
- Integrative transcriptome analysis identifies a crotonylation gene signature for predicting prognosis and drug sensitivity in hepatocellular carcinoma.
- A TiN-based nanophotosensitizer for enhanced photothermal therapy with the aid of ultrasound.
- Alternative splicing of IRF3 plays an important role in the development of hepatocarcinoma.
- Characterization of prognostic value and immunological roles of RAB22A in hepatocellular carcinoma.
- TMEM147 aggravates the progression of HCC by modulating cholesterol homeostasis, suppressing ferroptosis, and promoting the M2 polarization of tumor-associated macrophages.
- Triptonide inhibits growth and metastasis in HCC by suppressing EGFR/PI3K/AKT signaling.
- Targeting SLP2-mediated lipid metabolism reprograming restricts proliferation and metastasis of hepatocellular carcinoma and promotes sensitivity to Lenvatinib.
- RNF125 attenuates hepatocellular carcinoma progression by downregulating SRSF1-ERK pathway.
- Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
- Cytochrome B5 type A alleviates HCC metastasis via regulating STOML2 related autophagy and promoting sensitivity to ruxolitinib.
- Long non-coding RNA TPTEP1 exerts inhibitory effects on hepatocellular carcinoma by impairing microRNA-454-3p-mediated DLG5 downregulation.
- ANP32 Family as Diagnostic, Prognostic, and Therapeutic Biomarker Related to Immune Infiltrates in Hepatocellular Carcinoma.
- Impact of concurrent splenectomy and esophagogastric devascularization on surgical outcomes of partial hepatectomy for hepatocellular carcinoma in patients with clinically significant portal hypertension: A multicenter propensity score matc
- Identification of CFHR4 as a Potential Prognosis Biomarker Associated With lmmune Infiltrates in Hepatocellular Carcinoma.
- Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
- Efficacy and safety of preoperative transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.
- Upregulation Mitochondrial Carrier 1 (MTCH1) Is Associated with Cell Proliferation, Invasion, and Migration of Liver Hepatocellular Carcinoma.
- TNF-α/NF-κB signaling epigenetically represses PSD4 transcription to promote alcohol-related hepatocellular carcinoma progression.
- Postoperative morbidity adversely impacts long-term oncologic prognosis following hepatectomy for hepatocellular carcinoma: A multicenter observational study.
- CXCR4 promotes gefitinib resistance of Huh7 cells by activating the c-Met signaling pathway.
- The PGC1α/NRF1-MPC1 axis suppresses tumor progression and enhances the sensitivity to sorafenib/doxorubicin treatment in hepatocellular carcinoma.
- Homoharringtonine inhibits the progression of hepatocellular carcinoma by suppressing the PI3K/AKT/GSK3β/Slug signaling pathway.
癌症
肺癌
Lung cancer2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 25 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 4 家医院列在肺癌下全国有 251 家医院列在肺癌下
截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的肺癌开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文25
- MYBL2 regulates the expression of CENPF in lung adenocarcinoma and promotes tumor development and metastasis through AKT pathway activation.
- CircRAPGEF5 Promotes LUAD by Mediating the HOXC6 Stability.
- C-FOS promotes the formation of neutrophil extracellular traps and the recruitment of neutrophils in lung metastasis of triple-negative breast cancer.
- M2 macrophage-derived exosomes promote cell proliferation, migration and EMT of non-small cell lung cancer by secreting miR-155-5p.
- Causal Associations Between Cystatin and Lung Cancer: A Two-Sample Mendelian Randomization Study.
- Non-invasively Discriminating the Pathological Subtypes of Non-small Cell Lung Cancer with Pretreatment 18F-FDG PET/CT Using Deep Learning.
- The clinical, molecular, and therapeutic implications of time from primary diagnosis to brain metastasis in lung and breast cancer patients.
- SLC12A8 promotes the migration and invasion of non-small cell lung cancer (NSCLC) cells.
- Impact of SARS-CoV-2 infection on immune cell cuproptosis in patients with lung adenocarcinoma via glutamine regulation.
- Exosomal miR-20b-5p Induces EMT and Enhances Progression in Non-Small Cell Lung Cancer Via TGFBR2 Downregulation.
- Learning curve for double-port video-assisted thoracoscopic lung segmentectomy: a propensity score matching study.
- Common immunological and prognostic features of lung and bladder cancer via smoking-related genes: PRR11 gene as potential immunotherapeutic target.
- Correlation between CT spectral quantitative parameters and expression levels of HIF-1α and ALX1 in non-small cell lung cancer.
- N6-methyladenosine-mediated LINC01087 promotes lung adenocarcinoma progression by regulating miR-514a-3p to upregulate centrosome protein 55.
- Targeting Pokemon is a novel strategy to suppress cancer aggressiveness of non-small cell lung cancer: Identification of Pokemon as ideal target for developing anti-NSCLC drugs.
- Association of plasma branched-chain amino acid with multiple cancers: A mendelian randomization analysis.
- E3 ubiquitin-protein ligase 2 inhibits cell proliferation, migration, and invasion of non-small cell lung cancer through ubiquitination of Notch1.
- A triple-classification for the evaluation of lung nodules manifesting as pure ground-glass sign: a CT-based radiomic analysis.
- A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells.
- Biological functions of nuclear-localized insulin receptor (IR) on A549 lung cancer cells.
- Prediction model based on 18F-FDG PET/CT radiomic features and clinical factors of EGFR mutations in lung adenocarcinoma.
- LncRNA MALAT1 aggravates oxygen-glucose deprivation/reoxygenation-induced neuronal endoplasmic reticulum stress and apoptosis via the miR-195a-5p/HMGA1 axis.
- Clinical significance of expression level of CX3CL1-CX3CR1 axis in bone metastasis of lung cancer.
- GOLM1 predicts poor prognosis of patients with NSCLC and is associated with the proliferation and chemo-sensitivity of cisplatin in NSCLC cells: bioinformatics analysis and laboratory validation.
- Function and mechanism exploration of zinc finger protein 64 in lung adenocarcinoma cell growth and metastasis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
- Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
- A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China
- A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
癌症
胰腺癌
Pancreatic cancer2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 23 篇,占 0.4%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 3 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下
截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胰腺癌开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文23
- RNF187 neddylation in pancreatic cancer activates malignancy via IQGAP1-dependent actin cytoskeleton rearrangement.
- Pancreatic Cancer in High-Income Asia-Pacific: A Population-Based Study.
- The role of LncRNA-MANCR induced by HIF-1α drive the malignant progression of pancreatic cancer by targeting miRNA-494/SIRT1 signaling axis under hypoxic conditions.
- The lncRNA ST18-AS1 suppresses pancreatic cancer progression by enhancing ST18 mRNA stability through anchoring FUS in the cytoplasm.
- Alcohol-induced C/EBP β-driven VIRMA decreases oxidative stress and promotes pancreatic ductal adenocarcinoma growth and metastasis via the m6A/YTHDF2/SLC43A2 pathway.
- TRPM4 expression predicts prognosis and modulates the immune microenvironment in pancreatic adenocarcinoma.
- Revealing a cancer-associated fibroblast-based risk signature for pancreatic adenocarcinoma through single-cell and bulk RNA-seq analysis.
- LncRNA CCAT1 participates in pancreatic ductal adenocarcinoma progression by forming a positive feedback loop with c-Myc.
- Dual Starvations Induce Pyroptosis for Orthotopic Pancreatic Cancer Therapy through Simultaneous Deprivation of Glucose and Glutamine.
- Tumor Cell Derived Lnc-FSD2-31:1 Contributes to Cancer-Associated Fibroblasts Activation in Pancreatic Ductal Adenocarcinoma Progression through Extracellular Vesicles Cargo MiR-4736.
- The application of single-cell sequencing in pancreatic neoplasm: analysis, diagnosis and treatment.
- Clinical application of Al18F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to 18F-FDG.
- DUSP2 recruits CSNK2A1 to suppress AKT1-mediated apoptosis resistance under hypoxic microenvironment in pancreatic cancer.
- m6A regulators are differently expressed and correlated with immune response of pancreatic adenocarcinoma.
- Caprin-1 influences autophagy-induced tumor growth and immune modulation in pancreatic cancer.
- circEIF3I facilitates the recruitment of SMAD3 to early endosomes to promote TGF-β signalling pathway-mediated activation of MMPs in pancreatic cancer.
- Identification of MIR600HG/hsa-miR-342-3p/ANLN network as a potential prognosis biomarker associated with lmmune infiltrates in pancreatic cancer.
- Diabetic Ferroptosis and Pancreatic Cancer: Foe or Friend?
- Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer.
- Identification of hub genes in chronic pancreatitis and analysis of association with pancreatic cancer via bioinformatic analysis.
- Dictamnine inhibits pancreatic cancer cell growth and epithelial-mesenchymal transition by blocking the PI3K/AKT signaling pathway.
- Invadopodia: A potential target for pancreatic cancer therapy.
- Chinese expert consensus of image-guided irreversible electroporation for pancreatic cancer.
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- The Mechanism of Enhancing the Anti-tumor Effects of CAR-T on PC by Gut Microbiota Regulation
- Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
- A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China
- Laparoscopic vs Open Pancreatectomy for Body and Tail Pancreatic Cancer
癌症
乳腺癌
Breast cancer2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 23 篇,占 0.1%。
- 牵头的开放试验
- 0
- 正在或即将招募
哈尔滨有 4 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
- 分期
- III期
- 开始
- 2025-07
- 发布
- 登记号
- NCT07047365
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 44 家列出的医院为研究中心兰州、北京、南京、南充、南宁、南昌、合肥、哈尔滨、唐山、天津、太原、宁波、安阳、徐州、成都、新乡、昆明、沈阳、泸州、洛阳、济南、海口、深圳、温州、潍坊、石家庄、蚌埠、襄阳、西宁、西安、贵阳、郑州、重庆、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文23
- A survival analysis of T1 stage breast cancer and nomogram development: based on the SEER database.
- Survival analysis of metachronous bilateral ectopic breast cancer utilizing the SEER database and the pioneering construction of a nomogram model.
- Immune-based molecular subtyping of triple-negative breast cancer via SNF-CC and functional validation of key immune-associated genes.
- Expression and prognostic impact of hypoxia- and immune escape-related genes in triple-negative breast cancer: A comprehensive analysis.
- C-FOS promotes the formation of neutrophil extracellular traps and the recruitment of neutrophils in lung metastasis of triple-negative breast cancer.
- Nomogram construction and survival analysis in T3N0M0 breast cancer: a SEER population-based analysis.
- A novel nomogram and survival analysis for different lymph node status in breast cancer based on the SEER database.
- Circulating lipids, lipid-lowering drug targets, and breast cancer risk: Comprehensive evidence from Mendelian randomization and summary data-based Mendelian randomization.
- Nomograms for predicting recurrence of HER2-positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics.
- The clinical, molecular, and therapeutic implications of time from primary diagnosis to brain metastasis in lung and breast cancer patients.
- CircRNA hsa_circ_0003528/miR-215 is considered a potential target for predictive prognosis and therapy for triple-negative breast cancer.
- Long non‑coding RNA DANCR aggravates breast cancer through the miR‑34c/E2F1 feedback loop.
- Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterations.
- Association of plasma branched-chain amino acid with multiple cancers: A mendelian randomization analysis.
- Silencing MFHAS1 Induces Pyroptosis via the JNK-activated NF-κB/Caspase1/ GSDMD Signal Axis in Breast Cancer.
- ING1 inhibits Twist1 expression to block EMT and is antagonized by the HDAC inhibitor vorinostat.
- Clinicopathological analysis and prognostic treatment study of angiosarcoma of the breast: a SEER population-based analysis.
- Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
- Analysis of prognostic risk factors in 3427 patients with invasive ductal carcinoma of breast: Results based on the SEER database.
- NDV-D90 inhibits 17β-estradiol-mediated resistance to apoptosis by differentially modulating classic and nonclassic estrogen receptors in breast cancer cells.
- The nomogram based on the 6-lncRNA model can promote the prognosis prediction of patients with breast invasive carcinoma.
- Phosphatidylserine-exposing tumor-derived microparticles exacerbate coagulation and cancer cell transendothelial migration in triple-negative breast cancer.
- Long-term oncologic safety of immediate reconstructive surgery in patients with invasive breast cancer: a retrospective matched-cohort study.
癌症
胶质瘤
Glioma2021–2025 年中国大陆作者发表的 7,081 篇胶质瘤 PubMed 英文论文中,这家医院牵头了 35 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 4 家医院列在胶质瘤下全国有 187 家医院列在胶质瘤下
截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胶质瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文35
- Hemorrhagic and ischemic risks of anti-VEGF therapies in glioblastoma.
- Bioinformatics Analysis Screening and Identification of Key Biomarkers and Drug Targets in Human Glioblastoma.
- Research landscape of glioma and inflammation over the past two decades.
- HSPA5-mediated glioma hypoxia tolerance promotes M2 macrophage polarization under hypoxic microenvironment.
- Bone morphogenetic protein 1 as a macromolecular pan-cancer biomarker modulating the immune microenvironment and malignant phenotypes in glioblastoma.
- Integrative spatial multi-omics identifies the TEK receptor tyrosine kinase as a central biomacromolecule of endothelial-immune interactions in glioblastoma.
- Ubiquitin-conjugating enzyme E2S decreases the sensitivity of glioblastoma cells to temozolomide by upregulating PGAM1 via the interaction with OTUB2.
- Hypoxia-Inducible Factor-1α Regulates BNIP3-Dependent Mitophagy and Mediates Metabolic Reprogramming Through Histone Lysine Lactylation Modification to Affect Glioma Proliferation and Invasion.
- Ho(III)-coordination Complex: Fluorescence Performances and Combined with Captopril-Hydrogels against Glioma.
- Investigating the Aidi injection mechanism for low-grade glioma based on the network pharmacology approach, The Cancer Genome Atlas (TCGA), and molecular docking technology.
- Integrated analysis of bulk and single-cell RNA sequencing reveals the impact of nicotinamide and tryptophan metabolism on glioma prognosis and immunotherapy sensitivity.
- UBE2S facilitates glioblastoma progression through activation of the NF-κB pathway via attenuating K11-linked ubiquitination of AKIP1.
- Etomidate inhibits tumor growth of glioblastoma by regulating M1 macrophage polarization.
- Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma.
- Immunostimulant In Situ Fibrin Gel for Post-operative Glioblastoma Treatment by Macrophage Reprogramming and Photo-Chemo-Immunotherapy.
- Proteogenomic characterization of ferroptosis regulators reveals therapeutic potential in glioblastoma.
- Evaluating glioma-associated microRNA by complementation on a biological nanosensor.
- LncRNA as potential biomarker and therapeutic target in glioma.
- Prevalence, risk factors and prognostic value of anxiety and depression in recurrent glioma patients.
- Identification of DNA Damage Repair Gene Signature as a Novel Prognostic Marker in Glioblastoma Multiforme.
- Oncogenic Forkhead box D3 antisense RNA 1 promotes cell survival and confers temozolomide resistance in glioblastoma cells through the miR-128-3p/WEE1 G2 checkpoint kinase axis.
- The Mechanisms of Current Platinum Anticancer Drug Resistance in the Glioma.
- Pan-cancer analysis of ASB3 and the potential clinical implications for immune microenvironment of glioblastoma multiforme.
- CCL2-targeted ginkgolic acid exerts anti-glioblastoma effects by inhibiting the JAK3-STAT1/PI3K-AKT signaling pathway.
- Chelerythrine inhibits the progression of glioblastoma by suppressing the TGFB1-ERK1/2/Smad2/3-Snail/ZEB1 signaling pathway.
- Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors.
- Identification of Prognostic Biomarkers for Glioblastoma Based on Transcriptome and Proteome Association Analysis.
- Simvastatin Inhibits Tumor Growth and Migration by Mediating Caspase-1-Dependent Pyroptosis in Glioblastoma Multiforme.
- IL-24 inhibits the malignancy of human glioblastoma cells via destabilization of Zeb1.
- Interfering with hyaluronic acid metabolism suppresses glioma cell proliferation by regulating autophagy.
- Double-targeting CDCA8 and E2F1 inhibits the growth and migration of malignant glioma.
- TMEM2 Combined with IDH and 1p19q in Refining Molecular Subtypes for Predicting Survival of Patients with Glioma.
- MSH6 Aggravates the Hypoxic Microenvironment via Regulating HIF1A to Promote the Metastasis of Glioblastoma Multiforme.
- Reminiscence therapy-based care program for reducing anxiety and depression in glioma survivors: A randomized controlled trial.
- Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma.
癌症
肝母细胞瘤
Hepatoblastoma2021–2025 年没有牵头肝母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 1 家医院列在肝母细胞瘤下全国有 86 家医院列在肝母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 2 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 21 篇,占 0.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 6 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文21
- Heterogeneous c-Met Activation in Osteosarcoma Dictates Synergistic Vulnerability to Combined c-Met Inhibition and Methotrexate Therapy.
- Harmine exerts anticancer effects through the ROS/p38 axis to induce autophagy and apoptosis in osteosarcoma.
- Extraskeletal Ewing Sarcoma of the Abdominopelvic Cavity Revealed by 18 F-FDG PET/CT.
- A strategy for challenging tumorous bone regeneration by borosilicate bioactive glass boosting moderate magnetic hyperthermia.
- Antitumor effects of cannabidiol (CBD) on osteosarcoma by targeting TNF-α/NF-κB/CCL5 signaling axis.
- NAT10 mediated ac4C acetylation driven m6A modification via involvement of YTHDC1-LDHA/PFKM regulates glycolysis and promotes osteosarcoma.
- A novel hypoxia- and lactate metabolism-related prognostic signature to characterize the immune landscape and predict immunotherapy response in osteosarcoma.
- M7G modification of FTH1 and pri-miR-26a regulates ferroptosis and chemotherapy resistance in osteosarcoma.
- Vitamin C enhances the sensitivity of osteosarcoma to arsenic trioxide via inhibiting aerobic glycolysis.
- Integration of single-cell sequencing and bulk expression data reveals chemokine signaling pathway in proliferating cells is associated with the survival outcome of osteosarcoma.
- RING finger gene 180 inhibits osteosarcoma progression through regulating chromobox homolog 4 ubiquitination.
- PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin.
- Bevacizumab attenuates osteosarcoma angiogenesis by suppressing MIAT encapsulated by serum-derived extracellular vesicles and facilitating miR-613-mediated GPR158 inhibition.
- The Subcellular Localization of IncRNA FAM230B in Osteosarcoma and Its Interaction with Early miR-203.
- LncRNA BACE1-AS promotes the progression of osteosarcoma through miR-762/SOX7 axis.
- Hydroxygenkwanin suppresses proliferation, invasion and migration of osteosarcoma cells via the miR‑320a/SOX9 axis.
- Involvement of miR-769-5p/Retinoic Acid Receptor Responder 1 Axis in the Progression of Osteosarcoma: Characterization of Potential Therapeutic Targets.
- Accurate Identification and Early Diagnosis of Osteosarcoma through CRISPR-Cas12a-Based Average Telomerase Activity Detection.
- Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer.
- NPR3, transcriptionally regulated by POU2F1, inhibits osteosarcoma cell growth through blocking the PI3K/AKT pathway.
- Long non‑coding RNA H19 regulates LASP1 expression in osteosarcoma by competitively binding to miR‑29a‑3p.
早期论文(2016–2020 年)26
- Camptothecin induced DDX5 degradation increased the camptothecin resistance of osteosarcoma.
- Downregulation of lncRNA SNHG12 reversed IGF1R-induced osteosarcoma metastasis and proliferation by targeting miR-195-5p.
- Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA-424 in osteosarcoma.
- Construction and Validation of Nomograms for Predicting the Prognosis of Juvenile Osteosarcoma: A Real-World Analysis in the SEER Database.
- NFIL3 Acts as a Nuclear Factor to Increase Osteosarcoma Progression.
- Albumin-bioinspired iridium oxide nanoplatform with high photothermal conversion efficiency for synergistic chemo-photothermal of osteosarcoma.
- Long noncoding RNA NORAD regulates cancer cell proliferation and migration in human osteosarcoma by endogenously competing with miR-199a-3p.
- Synergistic anti-tumor effects of arsenic trioxide and blue LED irradiation on human osteosarcoma.
- SIRT1-ZEB1-positive feedback promotes epithelial-mesenchymal transition process and metastasis of osteosarcoma.
- Non‑covalent proteasome inhibitor PI‑1840 induces apoptosis and autophagy in osteosarcoma cells.
- miR-590-3p is a novel microRNA which suppresses osteosarcoma progression by targeting SOX9.
- Chimaphilin inhibits human osteosarcoma cell invasion and metastasis through suppressing the TGF-β1-induced epithelial-to-mesenchymal transition markers via PI-3K/Akt, ERK1/2, and Smad signaling pathways.
- Targeting the FOXM1-regulated long noncoding RNA TUG1 in osteosarcoma.
- Construction and analysis of a ceRNA‑ceRNA network reveals two potential prognostic modules regulated by hsa‑miR‑335‑5p in osteosarcoma.
- MicroRNA-129-5p suppresses cell proliferation, migration and invasion via targeting ROCK1 in osteosarcoma.
- Deoxyelephantopin Induces Reactive Oxygen Species-Mediated Apoptosis and Autophagy in Human Osteosarcoma Cells.
- A novel mechanism of mTORC1-mediated serine/glycine metabolism in osteosarcoma development.
- MicroRNA-492 overexpression exerts suppressive effects on the progression of osteosarcoma by targeting PAK7.
- Berberine affects osteosarcoma via downregulating the caspase-1/IL-1β signaling axis.
- Circular RNA hsa-circ-0016347 promotes proliferation, invasion and metastasis of osteosarcoma cells.
- Single nucleotide polymorphism of hsa-miR-124a affects risk and prognosis of osteosarcoma.
- A single nucleotide polymorphism in the 3'-untranslated region of the KRAS gene disrupts the interaction with let-7a and enhances the metastatic potential of osteosarcoma cells.
- Identification of CD20, ECM, and ITGA as Biomarkers for Osteosarcoma by Integrating Transcriptome Analysis.
- Relationship Between P15 Gene Mutation and Formation and Metastasis of Malignant Osteosarcoma.
- Long noncoding RNA FGFR3-AS1 promotes osteosarcoma growth through regulating its natural antisense transcript FGFR3.
- MicroRNA-503 represses epithelial-mesenchymal transition and inhibits metastasis of osteosarcoma by targeting c-myb.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 5 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
这些数字背后的记录
早期论文(2016–2020 年)3
- Analysis of risk factors of gastrointestinal stromal tumors in different age groups based on SEER database.
- Identification of critical microRNAs in gastrointestinal stromal tumor patients treated with Imatinib.
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis.
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 7 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
这些数字背后的记录
牵头的论文3
- Single cell analysis reveals the roles and regulatory mechanisms of type-I interferons in Parkinson's disease.
- KDM1A-mediated upregulation of METTL3 ameliorates Alzheimer's disease via enhancing autophagic clearance of p-Tau through m6A-dependent regulation of STUB1.
- LncRNA nuclear-enriched abundant transcript 1 aggravates cerebral ischemia/reperfusion injury through activating early growth response-1/RNA binding motif protein 25 axis.
早期论文(2016–2020 年)3
- Ubiquitin-specific protease 22 is associated with poor prognosis in neuroblastoma.
- Upregulation of miR-34a by Inhibition of IRE1α Has Protective Effect against Aβ-Induced Injury in SH-SY5Y Cells by Targeting Caspase-2.
- Mitochondrial ferritin protects SH-SY5Y cells against H2O2-induced oxidative stress and modulates α-synuclein expression.
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 1 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
哈尔滨有 3 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Risk Stratification and MRD-driven Maintenance for MM After ASCT
- 分期
- 不分期
- 开始
- 2024-12
- 发布
- 登记号
- NCT06697483
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学人民医院;另有 2 家列出的医院为研究中心北京、哈尔滨
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文4
- Adhesion of Immunoglobulins to Band3 Promotes Increased Erythrocyte Sedimentation Rate in Multiple Myeloma.
- Visualizing immunotherapy for multiple myeloma worldwide from 2013 to 2023: A bibliometric analysis.
- Identification of key miRNA signature and pathways involved in multiple myeloma by integrated bioinformatics analysis.
- Mechanism of exosomal miR-155 derived from bone marrow mesenchymal stem cells on stemness maintenance and drug resistance in myeloma cells.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
血液疾病
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 1 家医院列在B 细胞急性淋巴细胞白血病下全国有 88 家医院列在B 细胞急性淋巴细胞白血病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的B 细胞急性淋巴细胞白血病开放试验。
血液疾病
淋巴瘤
Lymphoma2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.03%。
哈尔滨有 3 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL
- 分期
- 未注明
- 开始
- 2018-03
- 发布
- 登记号
- NCT03494296
年龄 18 岁 至 未注明(登记的条件)
牵头:哈尔滨医科大学附属第一医院哈尔滨
- 正在招募A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- 分期
- III期
- 开始
- 2025-09
- 发布
- 登记号
- NCT06973187
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 24 家列出的医院为研究中心上海、兰州、北京、南宁、南昌、南通、哈尔滨、大连、太原、宁波、徐州、成都、武汉、沈阳、泸州、温州、石家庄、福州、苏州、西宁、西安、郑州、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL
- A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
- Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
血液疾病
血栓性血小板减少性紫癜
Thrombotic thrombocytopenic purpura2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 1 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。
这些数字背后的记录
其他疾病
烟雾病
Moyamoya disease2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
哈尔滨有 1 家医院列在烟雾病下全国有 47 家医院列在烟雾病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Registry of Multicenter Brain-Heart Comorbidity in China
- 分期
- 未注明
- 开始
- 2012-01
- 发布
- 登记号
- NCT05961748
年龄 18 岁 至 未注明(登记的条件)
牵头:首都医科大学附属北京天坛医院;另有 4 家列出的医院为研究中心上海、北京、哈尔滨、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
冠心病
Coronary heart disease2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.2%。
- 牵头的开放试验
- 0
- 正在或即将招募
哈尔滨有 3 家医院列在冠心病下全国有 231 家医院列在冠心病下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
- 分期
- II期
- 开始
- 2026-07
- 发布
- 登记号
- NCT07521007
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、兰州、北京、合肥、哈尔滨、天津、广州、成都、杭州、武汉、福州、苏州、西安、长春、长沙
- 正在招募Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
- 分期
- IV期
- 开始
- 2025-11
- 发布
- 登记号
- NCT07110415
年龄 40 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、兰州、北京、南京、南宁、哈尔滨、大庆、大连、天津、宁波、广州、张家口、成都、杭州、汕头、沈阳、济南、深圳、湖州、烟台、珠海、石家庄、西安、贵阳、重庆、银川、长春、青岛
- 正在招募Registry of Multicenter Brain-Heart Comorbidity in China
- 分期
- 未注明
- 开始
- 2012-01
- 发布
- 登记号
- NCT05961748
年龄 18 岁 至 未注明(登记的条件)
牵头:首都医科大学附属北京天坛医院;另有 8 家列出的医院为研究中心上海、北京、哈尔滨、福州、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文8
- Application effect of task-oriented multi-dimensional nursing intervention in patients with coronary atherosclerotic heart disease and concurrent hypertension.
- Association between Troponin Elevation and Decreased Myocardial Blood Flow Reserve in Patients without Obstructive Coronary Artery Disease.
- Prognostic value of computed tomography-derived fractional flow reserve in patients with diabetes mellitus and unstable angina.
- Predicting coronary artery disease by carotid color doppler ultrasonography.
- Association of marine PUFAs intakes with cardiovascular disease, all-cause mortality, and cardiovascular mortality in American adult male patients with dyslipidemia: the U.S. National Health and Nutrition Examination Survey, 2001 to 2016.
- Characteristics of coronary artery ectasia and accompanying plaques: an optical coherence tomography study.
- Influence of obstructive sleep apnoea on coronary artery disease in a Chinese population.
- Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR).
中文论文(未计入)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
- Effect of FFRCT-angio in Functional Diagnosis of Coronary Artery Stenosis
- Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease
- Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia
- Efficacy and Safety of Low-dose Ticagrelor
- Effects of Different Doses of Ticagrelor on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease
- A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
- Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
- Registry of Multicenter Brain-Heart Comorbidity in China
- Efficacy and Safety of Colchicine After PCI
- Phitys I™ Percutaneous Left Ventricular Assist System Study
- Risk Evaluation by COronary CTA and Artificial IntelliGence Based fuNctIonal analyZing tEchniques - II
- CorVad Percutaneous Ventricular Assist System Study
- Risk Evaluation by COronary CTA and Artificial intelliGence Based fuNctIonal analyZing tEchniques - I
- Sensor-equipped Ultrathin Pressure Microcatheter Versus Pressure Wire for Physiological Measurements
其他疾病
脊柱侧弯
Scoliosis2021–2025 年中国大陆作者发表的 925 篇脊柱侧弯 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 1 家医院列在脊柱侧弯下全国有 107 家医院列在脊柱侧弯下
截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的脊柱侧弯开放试验。
这些数字背后的记录
牵头的论文2
- Clinical Results of 10-mm Endoscopic Minimally Invasive Interlaminar Decompression in the Treatment of Lumbar Spinal Stenosis with Degenerative Lumbar Scoliosis and Simple Lumbar Spinal Stenosis.
- Minimally Invasive Interlaminar Decompression with a 10-mm Endoscope and Microscope in Cases of Adult Degenerative Scoliosis.
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 3 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)3
- Retrospective Study of Effect of Fine Particulate Matter on Acute Exacerbation of Patients with Idiopathic Pulmonary Fibrosis.
- Lung myofibroblast transition and fibrosis is regulated by circ0044226.
- Combined pulmonary fibrosis and emphysema: a retrospective analysis of clinical characteristics, treatment and prognosis.
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 11 篇,占 1.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 3 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文11
- COMM domain containing 4 inhibits hephaestin and ferroportin to enhance neuronal ferroptosis by disturbing the Cu-Fe balance in amyotrophic lateral sclerosis.
- Inhibition of Salt-Inducible Kinase 2 Protects Motor Neurons From Degeneration in ALS by Activating Autophagic Flux and Enhancing mTORC1 Activity.
- Integrative genomics and functional immunology reveal Clostridia species as modulators of neuroinflammation in amyotrophic lateral sclerosis.
- Fisetin Attenuates Mutant SOD1 Aggregation in Amyotrophic Lateral Sclerosis via Nrf2-Mediated Autophagy Activation.
- DAPK1 induces motor neuron apoptosis in hSOD1G93A-linked amyotrophic lateral sclerosis via regulating the Xiap/JNK pathway.
- Multi-omics framework integrating genetics microbiome and immunity for understanding motor neuron degeneration pathogenesis.
- RBM5 induces motor neuron apoptosis in hSOD1G93A-related amyotrophic lateral sclerosis by inhibiting Rac1/AKT pathways.
- Roflupram alleviates autophagy defects and reduces mutant hSOD1-induced motor neuron damage in cell and mouse models of amyotrophic lateral sclerosis.
- BRD7 regulates cellular senescence and apoptosis in ALS by modulating p21 expression and p53 mitochondrial translocation respectively.
- SPY1 inhibits neuronal ferroptosis in amyotrophic lateral sclerosis by reducing lipid peroxidation through regulation of GCH1 and TFR1.
- Diphenyl diselenide protects motor neurons through inhibition of microglia-mediated inflammatory injury in amyotrophic lateral sclerosis.
早期论文(2016–2020 年)8
- Wild-type p53-induced phosphatase 1 down-regulation promotes apoptosis by activating the DNA damage-response pathway in amyotrophic lateral sclerosis.
- Neuroprotection by urate on the mutant hSOD1-related cellular and Drosophila models of amyotrophic lateral sclerosis: Implication for GSH synthesis via activating Akt/GSK3β/Nrf2/GCLC pathways.
- Spy1, a unique cell cycle regulator, alters viability in ALS motor neurons and cell lines in response to mutant SOD1-induced DNA damage.
- γ-Oryzanol mitigates oxidative stress and prevents mutant SOD1-Related neurotoxicity in Drosophila and cell models of amyotrophic lateral sclerosis.
- α-Lipoic acid attenuates oxidative stress and neurotoxicity via the ERK/Akt-dependent pathway in the mutant hSOD1 related Drosophila model and the NSC34 cell line of amyotrophic lateral sclerosis.
- Fisetin Exerts Antioxidant and Neuroprotective Effects in Multiple Mutant hSOD1 Models of Amyotrophic Lateral Sclerosis by Activating ERK.
- Downregulation of Homer1b/c in SOD1 G93A Models of ALS: A Novel Mechanism of Neuroprotective Effect of Lithium and Valproic Acid.
- Comparative Analysis of VOCs in Exhaled Breath of Amyotrophic Lateral Sclerosis and Cervical Spondylotic Myelopathy Patients.
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 2 家医院列在白塞病下全国有 139 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
这些数字背后的记录
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 4 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
牵头的论文2
其他疾病
先天性巨结肠
Hirschsprung disease2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 1 家医院列在先天性巨结肠下全国有 76 家医院列在先天性巨结肠下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。
联系这家医院
出示给工作人员或司机的院名卡
哈尔滨医科大学附属第一医院
First Affiliated Hospital of Harbin Medical University
哈尔滨
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药